Study shows SL-NAD+ sublingual wafer has 22% bioavailability, bypassing digestive system and enhancing cellular NAD+ levels.

A study by iX Biopharma reveals that SL-NAD+, a sublingual NAD+ wafer, effectively delivers NAD+ directly into cells, demonstrating a 22% bioavailability compared to intravenous methods. This innovative approach bypasses the digestive system, enhancing cellular NAD+ levels and potentially offering a more convenient alternative to IV therapy. NAD+ is crucial for energy production, metabolism, DNA repair, and healthy aging, making this development significant for age-related health management.

September 02, 2024
6 Articles